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In a small study with 20 patients suffering from psoriatic arthritis,
Hammamoto et al have investigated TNF-a promoter polymorph-
isms and failed to con®rm the previously published (HoÈhler et al,
1997; Arias et al, 1997) association of psoriatic arthritis and psoriasis
with a G to A transition polymorphism (TNF238.A) in the TNF-a
promoter region. This polymorphism has attracted particular
interest as it seems to in¯uence the transcription of the TNF-a
gene and decreases the production of TNF-a in particular by T
lymphocytes (Kaluza et al, 2000). We have forwarded the
hypothesis that this polymorphism could be an additional major
histocompatibility complex (MHC) encoded susceptibility factor
for the development of psoriasis favoring persistence of cutaneous
skin infections, e.g. by streptococci. The TNF238A polymorphism
is part of the ancestral haplotype B57.1 (TNF238.A-B57-Cw6) that
has been linked to psoriasis. This is the most common haplotype in
Western European Caucasians with the disease (Jenisch et al, 1999).
In addition, a number of other haplotypes have been associated
with the occurrence of psoriasis, e.g. B13-Cw6, B8-Cw7, and
B37-Cw6 (Jenisch et al, 1999), the latter being the most common
disease associated haplotype in Japan (Imanishi et al, 1992). The
strong haplotype conservation within the MHC makes the
investigation of TNF-a polymorphisms in conjunction with
HLA-B and Cw-alleles mandatory. Unfortunately, Hamamoto
et al do not provide any data concerning HLA-B- and -Cw-allele
haplotypes and frequencies in their psoriatic arthritis group.
Considering the high frequency of the B37-Cw6 haplotype in
Japanese psoriasis patients (Imanishi et al, 1992) it is not surprising
that the authors do not ®nd an association with the TNF238.A
promoter variant, which is almost exclusively found on the B57-
Cw6 haplotype. Nevertheless, the ®ndings of this small study are
interesting as they underline ethnic heterogeneity in the genetics of
psoriasis. These results should be con®rmed in a larger set of
Japanese patients with psoriasis vulgaris and psoriatic arthritis
including HLA-B and Cw alleles in the analysis.
Very recent data by Nair et al (2000) indicate that the MHC
encoded PSORS1 susceptibility locus, which has been con®rmed
in a number of different studies, is located 100 kB telomeric to
HLA-C. This group has identi®ed a 60 kB fragment of the ancestral
haplotype 57.1 that is shared by all identi®able risk haplotypes.
Table I. TNF-a gene promoter polymorphism in 20 Japanese PsA patients and 87 controls
PsA Control
Position Genotype Number (%) Allele (frequency, %) Number (%) Allele (frequency, %)
T/T 16 (80.0) 65 (74.7)
±1,301T (90.0) ±1,301T (87.4)
±1301 T/C 4 (20.0) 22 (25.3)
±1,301C (10.0) ±1,301C (12.6)
C/C 0 (0.0) 0 (0.0)
C/C 15 (75.0) 63 (72.4)
±863C (85.0) ±863C (84.5)
±863 C/A 4 (20.0) 21 (24.1)
±863A (15.0) ±863A (15.5)
A/A 1 (5.0) 3 (3.5)
C/C 14 (70.0) 62 (71.3)
±857C (82.5) ±857C (84.5)
±857 C/T 5 (25.0) 23 (26.4)
±857T (17.5) ±857T (15.5)
T/T 1 (5.0) 2 (2.3)
G/G 20 (100) 83 (95.4)
±308G (100.0) ±308G (97.1)
±308 G/A 0 (0) 3 (3.4)
±308A (0.0) ±308A (2.9)
A/A 0 (0) 1 (5.0)
G/G 20 (100) 83 (95.4)
±238G (100.0) ±238G (97.7)
±238 G/A 0 (0) 4 (4.6)
±238A (0.0) ±238A (2.3)
A/A 0 (0) 0 (0.0)
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Nevertheless the TNF238.2 polymorphism on the B57.1
haplotype could characterize psoriasis patients with a particular
disease course or be related to an impaired clearance of skin
infections with candida or steptococci, and thus predispose
individuals to the development of psoriasis.
Thomas HoÈhler
Medizinische Klinik und Poliklinik,
Johannes Gutenberg-UniversitaÈt Mainz, Mainz, Germany,
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IgA Antibodies of Linear IgA Bullous Dermatosis Recognize
the 15th Collagenous Domain of BP180
To the Editor:
Linear IgA bullous dermatosis (LAD) is an autoimmune blistering
disease characterized by IgA antibodies against epidermal autoanti-
gens. The antigen for the major type of LAD (lamina lucida type)
was reported to be a 97 kDa protein (Zone et al, 1990;
Dmochowski et al, 1993; Ishiko et al, 1998) or 120 kDa protein
(Marinkovich et al, 1996). The 97 kDa/120 kDa protein was found
to be a degradation product of the 180 kDa bullous pemphigoid
antigen (BP180) (Marinkovich et al, 1997; Pas et al, 1997; Hirako
et al, 1998; Zone et al, 1998). To further characterize the antigenic
sites in LAD, we performed immunoblot studies using various
bacterial recombinant proteins of BP180.
Fourteen sera were collected from clinically typical LAD
patients and showed IgA antibodies reactive with epidermal side
of 1 M NaCl-split skin sections with a titer 1:10±1:40 in
immuno¯uorescence. Ten BP sera and 10 normal sera were
used as controls. A monoclonal antibody D-20, which reacts
with the 120 kDa LAD antigen (Hirako et al, 1998) and an
antiglutathione-S-transferase (GST) rabbit antiserum (Sigma, St.
Louis, MO) were also included as controls. Normal human
epidermal extracts (Dmochowski et al, 1993) and concentrated
supernatant of cultured DJM-1 cells (Hirako et al, 1998) and six
different GST-fusion proteins of BP180, i.e., NC16A, BP1050,
BP963, BP915, BPC15, and BP144, were used as antigen
sources for immunoblotting. The ®rst four fusion proteins were
reported previously (Matsumura et al, 1996; Nie and
Hashimoto, 1999). BP1050, BP963, and BP915 encode N-
terminus, central part, and C-terminus of BP180 extracellular
domain, respectively. By the similar method described pre-
viously (Matsumura et al, 1996; Nie et al, 1999), we prepared
two new recombinant proteins; BPC15 encoding the entire
15th collagenous domain, present just downstream of the
NC16a domain; and BP144 encoding 38 amino acids, which
is further downstream of BPC15, corresponding to the C-
terminal region of BP1050. NC16A, BPC15, and BP144 cover
the entire BP1050, although BP1050 lacks the N-terminus of
the NC16a domain. The constructs for BPC15 and BP144
were con®rmed by DNA sequencing and their correct sizes
(about 46 kDa for BPC15 and about 31 kDa for BP144) as
revealed by anti-GST antiserum in immunoblotting. The
positions of all the recombinant proteins are depicted in Fig 1.
All the results of immunoblotting were summarized in Table I.
In immunoblotting of epidermal extracts, none of the 14 LAD sera
showed speci®c IgA reactivity either with BP180 or with protein
bands in 97 kDa/120 kDa areas, whereas BP180 was detected by
IgG antibodies of 60% BP sera. In contrast, in immunoblotting of
concentrated culture supernatant of DJM-1 cells, IgA antibodies of
12 LAD sera clearly reacted with a 120 kDa protein (Fig 2, panel 1).
This protein was also reacted by IgG antibodies of six BP sera and
the monoclonal antibody D-20.
Because BP1050, BP963, and BP915 roughly cover the
whole extracellular domain of BP180, we ®rst examined IgA
reactivity of the 14 LAD sera with these fusion proteins. Seven
LAD sera reacted clearly with BP1050 (Fig 2, panel 2), and four
sera reacted relatively weakly with BP915 (data not shown),
whereas no LAD sera reacted with BP963. BP1050 is a large
fragment containing 350 amino acids. To further characterize
the epitope(s) within BP1050, we examined IgA reactivity of
LAD sera with three other fusion proteins, i.e., NC16A,
BPC15, and BP144, which in total cover BP1050. Interestingly,
®ve of the 11 LAD sera examined reacted with BPC15 (Fig 2,
panel 3), whereas no sera reacted with either NC16A (Fig 2,
panel 4) or BP144. The monoclonal antibody D-20 also
recognized BP1050 and BPC15, but not other fusion proteins.
As expected, IgG antibodies of the control BP sera reacted with
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Figure 1. Schematic structure of BP180 and the positions of the
recombinant fusion proteins used in this study. An oval in the left
indicates the transmembrane domain, gray columns indicate the collage-
nous domains, and open columns indicate noncollagenous domains of
BP180. Recombinant proteins of C-terminal extracellular region of BP180
are aligned in the corresponding positions of BP180.
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